alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2014388EN.01003301.xml

| 3.11.2014 | EN | Official Journal of the European Union | C 388/33 |
| --- | --- | --- | --- |

3.11.2014

EN

Official Journal of the European Union

C 388/33

---

Action brought on 1st September 2014 — ZZ and others v European Commission

(Case F-86/14)

2014/C 388/43

Language of the case: English

Parties

Parties

Applicants: ZZ and others (represented by: O. Mader, lawyer)

Applicants:

Defendant: European Commission

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

Annulment of the decisions reducing the total number of days of annual leave and declaration of inapplicability of Article 6 of Annex X to the Staff Regulations as modified by Article 1, point 70 of Regulation no 1023/2013, applicable from 1st January 2014.

o

st

Form of order sought

Form of order sought

| — | Annul the decisions addressed to the applicants through Sysper2 with regard to their new basic annual leave entitlement; |
| --- | --- |

—

Annul the decisions addressed to the applicants through Sysper2 with regard to their new basic annual leave entitlement;

| — | declare inapplicable Article 1, point 70 lit. (a) of Regulation (EU, Euratom) No. 1023/20131 changing Article 6 of Annex X of the Staff Regulations (‘Special and exceptional provisions applicable to officials serving in a third country’) and the Commission’s decision C(2013) 9051 final of 16 December 2013, as far they reduce the entitlement in number of annual leave days of the applicants; |
| --- | --- |

—

declare inapplicable Article 1, point 70 lit. (a) of Regulation (EU, Euratom) No. 1023/20131 changing Article 6 of Annex X of the Staff Regulations (‘Special and exceptional provisions applicable to officials serving in a third country’) and the Commission’s decision C(2013) 9051 final of 16 December 2013, as far they reduce the entitlement in number of annual leave days of the applicants;

| — | annul the Commission decision of 23 May 2014 (R/123/14) rejecting the complaints of the applicants, as far as referring to annual leave; |
| --- | --- |

—

annul the Commission decision of 23 May 2014 (R/123/14) rejecting the complaints of the applicants, as far as referring to annual leave;

| — | order the defendant to pay the costs. |
| --- | --- |

—

order the defendant to pay the costs.

---
# L_2019304EN.01000101.xml

| 26.11.2019 | EN | Official Journal of the European Union | L 304/1 |
| --- | --- | --- | --- |

26.11.2019

EN

Official Journal of the European Union

L 304/1

---

COUNCIL DECISION (EU, Euratom) 2019/1945

of 19 November 2018

approving the conclusion, by the European Commission, of the Agreement between the European Atomic Energy Community (Euratom) and the Korean Peninsula Energy Development Organisation (KEDO)

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty establishing the European Atomic Energy Community (Euratom), and in particular the second paragraph of Article 101 thereof,

Having regard to the recommendation from the European Commission,

Whereas:

| (1) | With a view to the protection of Euratom’s interests, membership of KEDO should continue beyond May 2015 in order to allow for a final settlement of legal and financial issues relating to the termination of KEDO’s nuclear light water reactor project and an orderly winding up of KEDO. |
| --- | --- |

(1)

With a view to the protection of Euratom’s interests, membership of KEDO should continue beyond May 2015 in order to allow for a final settlement of legal and financial issues relating to the termination of KEDO’s nuclear light water reactor project and an orderly winding up of KEDO.

| (2) | The Agreement between the European Atomic Energy Community (Euratom) and Korean Peninsula Energy Development Organisation (KEDO) should be concluded, |
| --- | --- |

(2)

The Agreement between the European Atomic Energy Community (Euratom) and Korean Peninsula Energy Development Organisation (KEDO) should be concluded,

HAS ADOPTED THIS DECISION:

Sole article

The conclusion by the European Commission of the Agreement between the European Atomic Energy Community (Euratom) and the Korean Peninsula Energy Development Organisation (KEDO) is hereby approved.

The text of the Agreement is attached to this Decision.

Done at Brussels, 19 November 2018.

For the Council

The President

F. MOGHERINI

---
#### § 601.45 Promotional materials.

For biological products being considered for approval under this subpart, unless otherwise informed by the agency, applicants must submit to the agency for consideration during the preapproval review period copies of all promotional materials, including promotional labeling as well as advertisements, intended for dissemination or publication within 120 days following marketing approval. After 120 days following marketing approval, unless otherwise informed by the agency, the applicant must submit promotional materials at least 30 days prior to the intended time of initial dissemination of the labeling or initial publication of the advertisement.
<PAGE>   1

                         EXHIBIT 24.1 POWER OF ATTORNEY

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears
below constitutes and appoints Gordon L. Ellis his attorney-in-fact, each with
the power of substitution, for him in any and all capacities, to sign any
amendments to this Report on Form 10-K, and to file same, with exhibits thereto
and other documents in connection therewith, with the U.S. Securities and
Exchange Commission, hereby ratifying and confirming all that said
attorney-in-fact, or his substitutes, may do or cause to be done by virtue
hereof.

        Pursuant to the requirements of the Securities Exchange Act of 1934,
this Report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.

<TABLE>
SIGNATURE                             TITLE                                      DATE

<S>                                   <C>                                        <C> 
/S/ GORDON ELLIS                      Chairman of the Board of Directors            June 26, 1998
-----------------------------                                                     ------------------
Gordon L. Ellis

/s/ Larry Flanagan                    CEO & President, Director                     June 26, 1998
-----------------------------                                                     ------------------
E. Laughlin Flanagan

/s/ William Maligie                   CEO & President AMT USA, Director             June 26, 1998
-----------------------------                                                     ------------------
William A. Maligie

/s/ Jim Sanders                       Chief Financial Officer                       June 26, 1998
-----------------------------                                                     ------------------
James B. Sanders

/s/ Will Walls                        Secretary                                     June 26, 1998
-----------------------------                                                     ------------------
William Walls

/s/ Stephen Silbernagel               Director                                      June 26, 1998
-----------------------------                                                     ------------------
Stephen H. Silbernagel

/s/ John Sutherland                   Director                                      June 26, 1998
-----------------------------                                                     ------------------
John J. Sutherland

/s/ Darryl Jones                      Director                                      June 26, 1998
-----------------------------                                                     ------------------
Darryl F. Jones

/s/ Gerald Habib                      Director                                      June 26, 1998
-----------------------------                                                     ------------------
 Gerald A. Habib
</TABLE>
# C_2014071EN.01001301.xml

| 8.3.2014 | EN | Official Journal of the European Union | C 71/13 |
| --- | --- | --- | --- |

8.3.2014

EN

Official Journal of the European Union

C 71/13

---

Action brought on 27 January 2014 — Kingdom of Spain v European Parliament and Council of the European Union

(Case C-44/14)

(2014/C 71/22)

Language of the case: Spanish

Parties

Applicant: Kingdom of Spain (represented by: A. Rubio González, Agent)

Defendants: European Parliament and Council of the European Union

Form of order sought

The applicant claims that the Court should:

| — | annul Article 19 of Regulation (EU) No 1052/2013 of the European Parliament and of the Council of 22 October 2013 (1) establishing the European Border Surveillance System (Eurosur); |
| --- | --- |

—

annul Article 19 of Regulation (EU) No 1052/2013 of the European Parliament and of the Council of 22 October 2013 (1) establishing the European Border Surveillance System (Eurosur);

| — | order the European Parliament and Council of the European Union to pay the costs. |
| --- | --- |

—

order the European Parliament and Council of the European Union to pay the costs.

Pleas in law and main arguments

Infringement of Article 4 of the Schengen Protocol in conjunction with Article 5 thereof.
  Article 19 of the Eurosur Regulation establishes an ad hoc procedure for the participation of the United Kingdom and Ireland through cooperation agreements. It therefore establishes a procedure for the participation of those Member States distinct from that provided for in Article 4 of the Schengen Protocol, effectively placing the United Kingdom and Ireland in the position of a third country outside the European Union.

---

(1)  OJ 2013 L 295, p. 11.

---
#### § 600.13 Retention samples.

Manufacturers shall retain for a period of at least 6 months after the expiration date, unless a different time period is specified in additional standards, a quantity of representative material of each lot of each product, sufficient for examination and testing for safety and potency, except Whole Blood, Cryoprecipitated AHF, Platelets, Red Blood Cells, Plasma, and Source Plasma and Allergenic Products prepared to a physician's prescription. Samples so retained shall be selected at random from either final container material, or from bulk and final containers, provided they include at least one final container as a final package, or package-equivalent of such filling of each lot of the product as intended for distribution. Such sample material shall be stored at temperatures and under conditions which will maintain the identity and integrity of the product. Samples retained as required in this section shall be in addition to samples of specific products required to be submitted to the Center for Biologics Evaluation and Research or the Center for Drug Evaluation and Research (see mailing addresses in § 600.2). Exceptions may be authorized by the Director, Center for Biologics Evaluation and Research or the Director, Center for Drug Evaluation and Research, when the lot yields relatively few final containers and when such lots are prepared by the same method in large number and in close succession.

[41 FR 10428, Mar. 11, 1976, as amended at 49 FR 23833, June 8, 1984; 50 FR 4133, Jan. 29, 1985; 55 FR 11013, Mar. 26, 1990; 70 FR 14982, Mar. 24, 2005]
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Paid Leave Provisions in Major Contracts: 1961: Vacations, Holidays, Jury Duty, Funeral Leave

              																	United States. Bureau of Labor Statistics. 						*Paid Leave Provisions in Major Contracts: 1961: Vacations, Holidays, Jury Duty, Funeral Leave : Bulletin of the United States Bureau of Labor Statistics, No. 1342*,												Washington, D.C: 								G.P.O., 										October 1962,									https://fraser.stlouisfed.org/title/4807,			accessed on September 26, 2024.						    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
# C_2014142EN.01001401.xml

| 12.5.2014 | EN | Official Journal of the European Union | C 142/14 |
| --- | --- | --- | --- |

12.5.2014

EN

Official Journal of the European Union

C 142/14

---

Request for a preliminary ruling from the Verwaltungsgerichtshof (Austria) lodged on 10 February 2014 — Finanzamt Linz v Bundesfinanzgericht, Außenstelle Linz

(Case C-66/14)

2014/C 142/18

Language of the case: German

Referring court

Referring court

Verwaltungsgerichtshof

Parties to the main proceedings

Parties to the main proceedings

Applicant: Finanzamt Linz

Applicant:

Defendant authority: Bundesfinanzgericht, Außenstelle Linz

Defendant authority:

Parties concerned: IFN-Holding AG, IFN Beteiligungs GmbH

Parties concerned:

Questions referred

Questions referred

| 1. | Does Article 107 TFEU (ex Article 87 EC), in conjunction with Article 108(3) TFEU (ex Article 88(3) EC), preclude a national measure under which, in the context of group taxation, goodwill is to be amortised in the case where a holding is acquired in a domestic company — thereby reducing the basis of assessment for tax purposes, and hence the tax burden — whereas such amortisation of goodwill on acquisition of a holding is not permissible in other cases of income and corporation tax? |
| --- | --- |

1.

Does Article 107 TFEU (ex Article 87 EC), in conjunction with Article 108(3) TFEU (ex Article 88(3) EC), preclude a national measure under which, in the context of group taxation, goodwill is to be amortised in the case where a holding is acquired in a domestic company — thereby reducing the basis of assessment for tax purposes, and hence the tax burden — whereas such amortisation of goodwill on acquisition of a holding is not permissible in other cases of income and corporation tax?

| 2. | Does Article 49 TFEU (ex Article 43 EC), in conjunction with Article 54 TFEU (ex Article 48 EC), preclude legal provisions of a Member State under which, in the context of group taxation, goodwill is to be amortised in the case where a holding is acquired in a domestic company, whereas such amortisation of goodwill may not be carried out in regard to acquisition of a holding in a non-resident corporation (in particular, a corporation established in another EU Member State)? |
| --- | --- |

2.

Does Article 49 TFEU (ex Article 43 EC), in conjunction with Article 54 TFEU (ex Article 48 EC), preclude legal provisions of a Member State under which, in the context of group taxation, goodwill is to be amortised in the case where a holding is acquired in a domestic company, whereas such amortisation of goodwill may not be carried out in regard to acquisition of a holding in a non-resident corporation (in particular, a corporation established in another EU Member State)?

---
cc: Hon. Lidia Stiglich, District Judge Oldenburg Law Office Attorney General/Carson City Washoe County District Attorney Washoe District Court Clerk

SUPREME COURT OF NEVADA

(0) 1947A caP(c) 2
§ 530.24 Procedure for announcing analytical methods for drug residue quantification. ( a ) FDA may issue an order announcing a specific analytical method or methods for the quantification of extralabel use drug residues above the safe levels established under § 530.22 for extralabel use of an approved human drug or an approved animal drug. The agency will publish in the Federal Register a notice of the order, including the name of the specific analytical method or methods and the drug or drugs for which the method is applicable.
( b ) Copies of analytical methods for the quantification of extralabel use drug residues above the safe levels established under § 530.22 will be available upon request from the Communications and Education Branch (HFV-12), Division of Program Communication and Administrative Management, Center for Veterinary Medicine, 7500 Standish Pl., Rockville, MD 20855. When an analytical method for the detection of extralabel use drug residues above the safe levels established under § 530.22 is developed, and that method is acceptable to the agency, FDA will incorporate that method by reference.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from IDS Managed
Futures II, L.P. for the second quarter of 1997 and is qualified in its entirety
by reference to such 10-Q.
</LEGEND>
<CIK> 0000813831
<NAME> IDS MANAGED FUTURES II, L.P.
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               JUN-30-1997
<CASH>                                      11,740,465
<SECURITIES>                                         0
<RECEIVABLES>                                   36,167
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            11,776,632
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                              11,776,632
<CURRENT-LIABILITIES>                          227,615
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                  11,549,017
<TOTAL-LIABILITY-AND-EQUITY>                11,776,632
<SALES>                                              0
<TOTAL-REVENUES>                             (613,958)
<CGS>                                                0
<TOTAL-COSTS>                                  261,048
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              (875,007)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          (875,007)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (875,007)
<EPS-PRIMARY>                                  (43.38)
<EPS-DILUTED>                                  (43.38)
        

</TABLE>
#### State of Connecticut *v.*Willis Collins et al.

*Louis I. Parley*and *Paul R. Rice,*in support of the petition.

Submitted December 10

decided December 16, 1969

The petition by the defendants for an expedited and preferential review by this court of the bond set by the Circuit Court in the fourteenth circuit and subsequently reduced by the Appellate Division of the Circuit Court is dismissed.
§ 522.1663 Oxytetracycline hydrochloride with lidocaine injection. ( a ) *Specifications.* The drug contains 50 or 100 milligrams of oxytetracycline hydrochloride and 2 percent lidocaine in each milliliter of sterile aqueous solution.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use.* ( 1 ) The drug is indicated for use in the treatment of diseases of dogs caused by pathogens sensitive to oxytetracycline hydrochloride including treatment for the following conditions in dogs caused by susceptible microorganisms: Bacterial infections of the urinary tract caused by *Hemolytic staphylococcus, Streptococcus spp.,* Bacterial pulmonary infections caused by *Brucella bronchiseptica, Streptococcus pyogenes, Staphylococcus aureus,* secondary bacterial infections caused by *Micrococcus pyogenes var. albus, Brucella bronchiseptica, Streptococcus spp.*
( 2 ) The drug is administered intramuscularly at a recommended daily dosage to dogs at 5 milligrams per pound of body weight administered in divided doses at 6 to 12 hour intervals. Therapy should be continued for at least 24 hours after all symptoms have subsided.
( 3 ) Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[40 FR 13858, Mar. 27, 1975, as amended at 48 FR 30615, July 5, 1983; 79 FR 16192, Mar. 25, 2014. Redesignated at 88 FR 14898, Mar. 10, 2023]
§ 660.25 Potency tests without reference preparations. Products for which Reference Blood Grouping Reagents are not available shall be tested for potency by a method approved by the Director, Center for Biologics Evaluation and Research. ( a ) *Potency requirements.* Blood Grouping Reagents recommended for the test tube methods, including the indirect antiglobulin tests, shall have the following potency titer values, unless other values are approved by the Director, Center for Biologics Evaluation and Research. ( 1 ) For Anti-K, Anti-k̄, Anti-Jka, Anti-Fya, Anti-Cw, at least 1 + reaction with a 1:8 dilution of the reagent.
( 2 ) For Anti-S, Anti-s̄, Anti-P1, Anti-M, Anti-I, Anti-e (saline), Anti-c̄ (saline), and Anti-A1, at least 1 + reaction with a 1:4 dilution of the reagent.
( 3 ) For Anti-U, Anti-Kpa, Anti-Kpb, Anti-Jsa, Anti-Jsb, Anti-Fyb, Anti-N, Anti-Lea, Anti-Leb, Anti-Lua, Anti-Lub, Anti-Dia, Anti-Mg, Anti-Jkb, Anti-Cob, Anti-Wra, and Anti-Xga, at least 2 + reaction with undiluted reagent.
( b ) *Products recommended for slide tests or microplate techniques.* Blood Grouping Reagent recommended for slide test methods or microplate techniques shall produce clearly positive macroscopic results when both undiluted reagent and reagent diluted with an equal volume of diluent are tested by all methods recommended in the manufacturer's package insert using red blood cells showing heterozygous or diminished expression of the corresponding antigen. The dilution shall be made with an equal volume of compatible serum or approved diluent.
( c ) *Products recomended for use in an automated system.* The manufacturer of Blood Grouping Reagent that is recommended for use in an automated system shall demonstrate that its product when used both undiluted and diluted with an equal volume of diluent satisfactorily performs when tested with cells representing heterozygous or diminished expression of the corresponding antigen.
[53 FR 12764, Apr. 19, 1988, as amended at 67 FR 9587, Mar. 4, 2002; 70 FR 14985, Mar. 24, 2005]
§ 630.25 Exceptions from certain donor eligibility requirements for infrequent plasma donors. For an infrequent plasma donor who is not participating in an immunization program, establishments are not required to: ( a ) Perform a medical history and physical examination of the donor under § 630.15(b)(1);
( b ) Perform a test for total protein under § 630.15(b)(4);
( c ) Determine the total plasma or serum protein and immunoglobulin composition under § 640.65(b)(1)(i) of this chapter; or
( d ) Review the data and records as required in § 640.65(b)(2)(i) of this chapter.